Click here to get full coverage on Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq

Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation  Nasdaq

Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq

Click here to get full coverage on Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory  Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6% - Should You Sell? - MarketBeat

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6% - Should You Sell?  MarketBeat

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6% - Should You Sell? - MarketBeat

Click here to get full coverage on Protagonist Therapeutics (PTGX) Target Price Raised by Barclays - GuruFocus

Protagonist Therapeutics (PTGX) Target Price Raised by Barclays  GuruFocus

Protagonist Therapeutics (PTGX) Target Price Raised by Barclays - GuruFocus

Click here to get full coverage on How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results - simplywall.st

How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results  simplywall.st

How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results - simplywall.st

Click here to get full coverage on Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - 富途牛牛

Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating  富途牛牛

Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - 富途牛牛

Click here to get full coverage on Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - Sahm

Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide  Sahm

Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - Sahm

Click here to get full coverage on Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?  Yahoo Finance

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Click here to get full coverage on Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Is Protagonist Therapeutics (PTGX) Overvalued After Its Recent Biotech Rally? A Fresh Look at the Valuation - Sahm

Is Protagonist Therapeutics (PTGX) Overvalued After Its Recent Biotech Rally? A Fresh Look at the Valuation  Sahm

Is Protagonist Therapeutics (PTGX) Overvalued After Its Recent Biotech Rally? A Fresh Look at the Valuation - Sahm

Click here to get full coverage on Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL  MarketBeat

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat

Click here to get full coverage on Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq

Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation  Nasdaq

Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq

Click here to get full coverage on Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge - Yahoo Finance

Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge  Yahoo Finance

Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge - Yahoo Finance

Click here to get full coverage on Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting - Yahoo Finance

Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting  Yahoo Finance

Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting - Yahoo Finance

Click here to get full coverage on Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? - Yahoo Finance

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?  Yahoo Finance

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? - Yahoo Finance

Click here to get full coverage on 683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX) - Seeking Alpha

Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX)  Seeking Alpha

Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX) - Seeking Alpha

Click here to get full coverage on HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - What's Next? - MarketBeat

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - What's Next?  MarketBeat

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - What's Next? - MarketBeat

Click here to get full coverage on Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - simplywall.st

Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide  simplywall.st

Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - simplywall.st

Click here to get full coverage on Sudden Surge: PTGX’s Momentous Journey - timothysykes.com

Sudden Surge: PTGX’s Momentous Journey  timothysykes.com

Sudden Surge: PTGX’s Momentous Journey - timothysykes.com

Click here to get full coverage on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts  MarketBeat

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Click here to get full coverage on $PTGX stock is up 31% today. Here's what we see in our data. - Quiver Quantitative

$PTGX stock is up 31% today. Here's what we see in our data.  Quiver Quantitative

$PTGX stock is up 31% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on New Analyst Forecast: $PTGX Given $80.0 Price Target | PTGX Stock News - Quiver Quantitative

New Analyst Forecast: $PTGX Given $80.0 Price Target | PTGX Stock News  Quiver Quantitative

New Analyst Forecast: $PTGX Given $80.0 Price Target | PTGX Stock News - Quiver Quantitative

Click here to get full coverage on Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more - CNBC

Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more  CNBC

Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more - CNBC

Click here to get full coverage on $PTGX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$PTGX stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$PTGX stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on M&A News: Protagonist Therapeutics Stock (PTGX) is Star of the Show on JNJ Bid Talk - TipRanks

M&A News: Protagonist Therapeutics Stock (PTGX) is Star of the Show on JNJ Bid Talk  TipRanks

M&A News: Protagonist Therapeutics Stock (PTGX) is Star of the Show on JNJ Bid Talk - TipRanks

Click here to get full coverage on Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade

Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This?  StocksToTrade

Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade

Click here to get full coverage on New Analyst Forecast: $PTGX Given $82.0 Price Target - Quiver Quantitative

New Analyst Forecast: $PTGX Given $82.0 Price Target  Quiver Quantitative

New Analyst Forecast: $PTGX Given $82.0 Price Target - Quiver Quantitative

Click here to get full coverage on Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on PTGX: Citigroup Raises Price Target and Maintains Buy Rating | P - GuruFocus

PTGX: Citigroup Raises Price Target and Maintains Buy Rating | P  GuruFocus

PTGX: Citigroup Raises Price Target and Maintains Buy Rating | P - GuruFocus

Click here to get full coverage on Protagonist Therapeutics (PTGX) Stock Surges Over 34% - GuruFocus

Protagonist Therapeutics (PTGX) Stock Surges Over 34%  GuruFocus

Protagonist Therapeutics (PTGX) Stock Surges Over 34% - GuruFocus

Click here to get full coverage on PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus

PTGX Stock Receives Positive Analyst Rating Update from Citigrou  GuruFocus

PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus

Click here to get full coverage on Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity  Yahoo Finance

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - Yahoo Finance

Click here to get full coverage on Insider Sale: Director at $PTGX Sells 4,000 Shares - Quiver Quantitative

Insider Sale: Director at $PTGX Sells 4,000 Shares  Quiver Quantitative

Insider Sale: Director at $PTGX Sells 4,000 Shares - Quiver Quantitative

Click here to get full coverage on Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ) - Seeking Alpha

Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ)  Seeking Alpha

Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Leading Biotech Protagonist Therapeutics Lines Up Three Major Investment Conferences This September - Stock Titan

Leading Biotech Protagonist Therapeutics Lines Up Three Major Investment Conferences This September  Stock Titan

Leading Biotech Protagonist Therapeutics Lines Up Three Major Investment Conferences This September - Stock Titan

Click here to get full coverage on Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues  simplywall.st

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st

Click here to get full coverage on How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

How (PTGX) Movements Inform Risk Allocation Models  news.stocktradersdaily.com

How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

Click here to get full coverage on Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Will PTGX stock recover faster than peers - July 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru

Will PTGX stock recover faster than peers - July 2025 Macro Moves & Free Community Consensus Stock Picks  ulpravda.ru

Will PTGX stock recover faster than peers - July 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru

Click here to get full coverage on 120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC - MarketBeat

120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC  MarketBeat

120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC - MarketBeat

Click here to get full coverage on New Analyst Forecast: $PTGX Given $102.0 Price Target - Quiver Quantitative

New Analyst Forecast: $PTGX Given $102.0 Price Target  Quiver Quantitative

New Analyst Forecast: $PTGX Given $102.0 Price Target - Quiver Quantitative

Click here to get full coverage on Noteworthy Monday Option Activity: JANX, AI, PTGX - Nasdaq

Noteworthy Monday Option Activity: JANX, AI, PTGX  Nasdaq

Noteworthy Monday Option Activity: JANX, AI, PTGX - Nasdaq

Click here to get full coverage on Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acqu - GuruFocus

Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acqu  GuruFocus

Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acqu - GuruFocus

Click here to get full coverage on Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs  ts2.tech

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech

Click here to get full coverage on OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX  MarketBeat

Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Click here to get full coverage on Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - The Motley Fool

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today  The Motley Fool

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - The Motley Fool

Click here to get full coverage on 84% Skin Clearance: Protagonist's Oral Psoriasis Drug Outperforms Injectable Treatment in Phase 3 Trial - Stock Titan

84% Skin Clearance: Protagonist's Oral Psoriasis Drug Outperforms Injectable Treatment in Phase 3 Trial  Stock Titan

84% Skin Clearance: Protagonist's Oral Psoriasis Drug Outperforms Injectable Treatment in Phase 3 Trial - Stock Titan

Click here to get full coverage on Protagonist Therapeutics surges after media reports J&J in talks to buy co - TradingView — Track All Markets

Protagonist Therapeutics surges after media reports J&J in talks to buy co  TradingView — Track All Markets

Protagonist Therapeutics surges after media reports J&J in talks to buy co - TradingView — Track All Markets

Click here to get full coverage on J&J reportedly in talks to buy Protagonist (JNJ:NYSE) - Seeking Alpha

J&J reportedly in talks to buy Protagonist (JNJ:NYSE)  Seeking Alpha

J&J reportedly in talks to buy Protagonist (JNJ:NYSE) - Seeking Alpha

Click here to get full coverage on Does Protagonist Therapeutics Offer Value After Major Pipeline Updates and Triple Digit 2024 Gains? - simplywall.st

Does Protagonist Therapeutics Offer Value After Major Pipeline Updates and Triple Digit 2024 Gains?  simplywall.st

Does Protagonist Therapeutics Offer Value After Major Pipeline Updates and Triple Digit 2024 Gains? - simplywall.st

Click here to get full coverage on Why Did Protagonist Therapeutics Stock Soar Today? - MSN

Why Did Protagonist Therapeutics Stock Soar Today?  MSN

Why Did Protagonist Therapeutics Stock Soar Today? - MSN

Click here to get full coverage on Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Jo - GuruFocus

Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Jo  GuruFocus

Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Jo - GuruFocus

Click here to get full coverage on Protagonist Therapeutics (PTGX) Surges on Takeover Speculation - GuruFocus

Protagonist Therapeutics (PTGX) Surges on Takeover Speculation  GuruFocus

Protagonist Therapeutics (PTGX) Surges on Takeover Speculation - GuruFocus

Click here to get full coverage on Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates  Nasdaq

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Yahoo Finance

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal  Yahoo Finance

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Yahoo Finance

Click here to get full coverage on Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)? - simplywall.st

Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)?  simplywall.st

Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)? - simplywall.st

Click here to get full coverage on Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks - TradingView — Track All Markets

Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks  TradingView — Track All Markets

Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks - TradingView — Track All Markets

Click here to get full coverage on Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - Reuters

Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says  Reuters

PTGX

Price Chart

Key Statistics

Technicals

About PTGX

Latest News

Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq

Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Yahoo Finance

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6% - Should You Sell? - MarketBeat

Advanced Charts

Top Gainers

Top Losers